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Humans have turned to natural products, obtained from plants, animals and 
aquatic life for treating diseases since time immemorial. Modern medicine is based 
on ancient wisdom transferred over generations. Drug development relies mainly 
on natural sources. Herbal medicines are making a comeback due to lower side 
effects, and positive results in the long term when compared to synthetic drugs. The 
current drug discovery process relies on identifying traditional medicines followed 
by Bioactivity-guided fractionation to isolate significant lead molecules. Plants have 
a history of long-term use by humans and hence it can be presumed that the bioac-
tive compounds obtained from plants will have low human toxicity. There exists 
a huge potential for discovering new antitumor drug leads by screening natural 
products either in the form of crude extracts purified phytochemicals which have 
already been described in the literature. The fact that phytochemicals like paclitaxel, 
vinblastine, vincristine and camptothecin are being successfully used in clinical 
practice and several others like combretastatin and noscapine are in different stages 
of clinical trials implies the importance of plants in cancer chemotherapy.
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1. Introduction
“Until man duplicates a blade of grass, nature can laugh at his so-called scientific 
knowledge. Remedies from chemicals will never stand in favourable comparison 
with the products of nature, the living cell of the plant, the final result of the rays of 
the sun, the mother of all life.” - Thomas Alva Edison.
The global cancer burden has escalated to 9.6 million deaths and 18.1 million new 
cases in 2018. It is a fact that one in 5 men and one in 6 women around the world 
develop cancer during their lifetime, and it kills one in 8 men and one in 11 women 
[1]. Cancer continues to be the second leading cause of death globally, the first 
being cardiovascular diseases. Patients with cancer normally have a poor prognosis 
in low and middle-income countries such as India, due to a lack of awareness about 
the disease, delayed diagnosis, and inadequate or no access to affordable therapeutic 
services when compared with patients in high-income countries. The number of 
incident cancer cases in India is estimated to be 1 069 000 in 2016. Access to critical 
cancer treatment is also very low in the country. It is the need of the day to find a 
natural, affordable treatment strategy for cancer [2].
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The conventional modality for cancer treatment involves the use of surgery, 
radiation and chemotherapy either alone or in combination with the others. Each 
of the treatment modality offers its risks and benefits. Although chemotherapeutic 
medicines are toxic and have a very narrow therapeutic index, they offer a tran-
sient relief from symptoms and help prolong life especially in the case of cancers 
where surgery and radiation is not a feasible mode of treatment like leukaemia and 
lymphomas. Chemotherapy is a systemic treatment because it can be used to treat 
cancer anywhere in the body when compared to local treatment approaches. The 
chemotherapeutic agents that are currently used in clinical practice lack specificity 
to the cancer cells and could damage the healthy cells causing adverse side effects. 
Toxicity and severe side effects continue to be significant setbacks involved in 
chemotherapeutic approaches to the treatment of cancer. To overcome the limita-
tions, scientists across the globe are searching for new anticancer agents with more 
specificity and fewer side effects. Many recent studies have found that an extensive 
array of natural substances exert selective toxicity against cancer cells by selectively 
eliminating them causing less harm to the normal cells [3].
Cragg and Newman et al. have identified that nearly 5% out of the 1031 new 
chemical entities approved for use as drug between 1981 and 2002, by the US FDA 
(Food and Drug Administration) were natural products and 23% were derived from 
natural products [4]. Some well-known plant secondary metabolites used as medi-
cine are paclitaxel, vinblastine, vincristine, artemisinin, atropine, inulin, digoxin, 
morphine and codeine, and quinine [5, 6]. Normal metabolism in plants produces 
a variety of chemical compounds. The primary metabolites are found ubiquitously 
like fats and sugars whereas the secondary metabolites are more specific to a 
particular genus or species. An advantage of plant metabolites is that apart from 
serving as functional drugs, they can be used as lead molecules for the synthesis of 
derivatives or synthetic molecules with the active pharmacophore.
2. Cancer and metastasis
The term ‘cancer’ refers to a range of diseases in which abnormal cells prolifer-
ate and spread uncontrollably in the body [7]. Under normal conditions, cells 
grow and multiply systematically to form organs and tissues that have a specific 
function. Occasionally, however, they multiply in an uncontrolled manner after 
developing a random genetic mutation or due to the influence of a carcinogen 
and form a mass known as a tumour or neoplasm that has no physiological func-
tion. It was Hippocrates (460–370 B.C.), the Greek physician who used the names 
‘carcinos’ and ‘carcinoma’ to define non-ulcer forming and ulcer-forming tumours. 
In Greek, carcinos and carcinoma mean ‘crab’; and the disease was named so 
because the finger-like projections extending from cancer resemble a crab in shape. 
Carcinomas, a type of cancer which arises from epithelial cells, is the most common 
type of cancer affecting people today. The first abnormality concerning cell matu-
ration to be evident microscopically is known as dysplasia. This, in turn, leads to 
architectural chaos, irregularity in the nucleus, augmented and abnormal mitoses, 
and an increase in the number of apoptotic cells.
Tumours in the body can be benign or malignant. Benign tumours are those 
which do not invade other tissues or spread to other parts of the body. Malignant 
tumours, however, can grow in an uncontrolled way and by a process known as 
metastasis, can spread within the body. Even though all tumours are diverse and 
heterogeneous, they share the capacity to proliferate beyond the constraints that 
limit the growth of healthy tissue [7]. They can spread by direct local invasion, 
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vascular spread, cerebrospinal fluid (CSF) spread, transcoelomic (peritoneal or 
pleural) spread or lymphatic spread.
Modifications in the regulation of some crucial pathways that control cell prolif-
eration (cell cycle) and survival (apoptosis) are responsible for creating all tumours 
[8]. The modifications include the loss of function of the tumour suppressor gene, 
oncogenic transformations, as well as modifications in the signal transduction path-
ways which leads to an augmented proliferation in response to external/mitogenic 
signals. As such, tumour-associated mutations in many of these pathways result in 
the alteration of the necessary regulatory mechanisms that control the mammalian 
cell cycle.
3. Cancer therapy
Surgery remains one of the foremost treatments for cancer. It has been men-
tioned by Roman doctor Gallien as a means of treating cancer as early as the 2nd 
century. It was followed by radiation therapy using radium and other diagnostic 
machines using relatively less voltage. Although the present methodology and the 
equipment for delivery of radiation therapy have improved allowing the oblitera-
tion of malignant tumours with great precision, this mode of therapy is limited 
by severe side effects and a restricted capacity to distinguish between healthy and 
tumour cells. Furthermore, both radiation and surgery are not beneficial in cases of 
advanced metastatic cancers.
Traditional treatments for cancer such as chemotherapy (e.g. anti-metabolites, 
alkylating agents, topoisomerase inhibitors) and radiation therapy were developed 
based upon the observation that transformed cells multiply at a higher rate when 
compared to normal cells. For example, ionising radiation results in DNA damage 
which, after multiple cell divisions, leads to errors in transcription and translation, 
eventually resulting in cell death [9]. In the same way, cytotoxic chemotherapy 
interferes with microtubule organisation, which is essential for mitosis and in 
due course, affects cell survival [10]. The same is true for various haematopoietic 
malignancies, however, as little as 5% of some solid tumours consist of rapidly 
proliferating, and therefore, susceptible cells. Hence, only a small subset of cancers 
such as Hodgkin’s lymphoma, testicular cancer, acute lymphoid leukaemia and 
non-Hodgkin’s lymphoma are routinely cured using these agents [11]. This is largely 
because therapies that are targeted against rapidly proliferating cells cause the death 
of normal tissues which also show enhanced proliferation rates, such as the gastro-
intestinal (GI) tract, bone marrow and the hair follicles [12].
4. Drug resistance
The development of drug resistance is also a major obstacle in patients receiving 
prolonged chemotherapeutic treatment. Clinical resistance to anticancer agents can 
occur at the time of drug introduction, as well as during treatment and following 
relapse [13]. Although various resistance mechanisms have been described, such 
as insufficient activation of the drug, utilisation of alternate metabolic pathways, 
mutations in the p53 gene and overexpression of the Bcl-2 gene family, the most 
intensely studied has been the decreased accumulation of drugs in cells, which 
is the leading cause of multi-drug resistance [14]. Such resistance is indicated 
by a failure to respond to a range of chemotherapeutic agents, many of which 
are structurally dissimilar and do not share a common intracellular target. The 
Alternative Medicine
4
mechanism responsible for Multidrug resistance in mammalian cells involves the 
overexpression of a 170 kDa cell surface, energy-dependent plasma membrane 
glycoprotein (P-gp) encoded on the MDR1 gene [15]. The physiological role of P-gp 
is the protection of cells against environmental toxins and works by exporting drugs 
outside of mammalian cells, thereby lowering the intracellular drug concentration 
less than the toxic threshold [16]. However, the chemotherapy of cancer, as com-
pared with that of bacterial disease, poses a critical problem. Microorganisms are 
quantitatively and qualitatively different from human cells, while, cancer cells and 
normal cells are so similar that it has proved difficult to find general, exploitable 
biochemical differences between them. This is exemplified by the number of drugs 
selected for preclinical or clinical testing, based on their activity in experimental 
animal systems, which do not become clinically useful agents due to their severe or 
unpredictable toxicity towards normal cells, or because they lack any therapeutic 
advantage. The prevalence of MDR and systemic toxicity associated with currently 
administered cancer chemotherapies therefore suggest the need for alternative pos-
sibilities to be investigated to find new and worthy therapeutic agents.
5. Apoptosis and the need for apoptotic inducers
The process of homeostasis in multicellular organisms is strongly regulated 
by a process known as PCD (programmed cell death) or apoptosis. When cells 
obtain diverse indications for growth they generally die. This happens when certain 
developmental processes call for cell division but there are no external growth 
signals when a growth-related gene, e.g. c-myc gets highly expressed but the cellular 
environment lacks nutrient content, and in the presence of a toxic xenobiotic and 
the cell dies by a process termed apoptosis. The term ‘apoptosis’ was used for the 
first time in 1972 in literature, to describe a structurally-distinctive method of cell 
death which caused the loss of cells within live tissues [17].
There are inherent cellular programs that direct a cell into self-destruction. 
Several occurrences helped establish this; e.g. in the nematode, Caenorhabditis 
elegans, it has been discovered observed that a set of 113 cells is destined for pro-
grammed cell death in the hermaphrodite form of the worm during embryogenesis, 
and a different set of 18 cells later in life, forming a total of 131 cells [18].
The key features include blebbing and shrinkage of the cytoplasm, conservation 
of cellular organelle structure, involving the mitochondria and the condensation 
and margination of chromatin, although all cell types do not show all of these 
characteristics. These changes are a consequence of a developmental program for 
cell death which is activated by the deficiency of a growth factor, or by the presence 
of a xenobiotic compound such as a therapeutic anticancer drug. The morphological 
criteria are still the most important when complex cell populations, such as tissues, 
are examined, and overall cell shrinkage and nuclear condensation are the easiest to 
recognise [19].
The discovery of about 30 novel molecules whose functions are completely 
related to the initiation or control of apoptosis has been made over the last decade. 
Another 20 molecules, associated with essential roles in cell signalling and DNA 
transcription, replication or repair, have been established as effectors of apoptosis 
regulation. The rate of apoptosis influences the lifespan of cells in the human body, 
both healthy and cancer cells. Thus, the modulation of apoptosis is useful in the 
deterrence, management and therapy of cancer. Synthesis of novel compounds 
based on existing templates continues to be an indispensable aspect of research. 
Natural products are capable of providing such templates. Latest studies on tumour 
inhibitory compounds originating from plants have given rise to a remarkable group 
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of unique structures. Moreover, epidemiological findings confirm the theory that 
following a diet containing plenty of fruits and vegetables which are key sources 
of micronutrients and phytochemicals, reduces the risk of acquiring cancer [20]. 
It has also been reported that some products from plants bring about apoptosis in 
neoplastic cells alone and not in normal cells [21].
There have been reports confirming the role of apoptosis as an essential mode of 
action for several anti-tumour agents, such as alkylating agents including the widely 
used cisplatin and 1,3- bis (2-chloroethyl)-1-nitrosourea (BCNU) [22], ionising 
radiation [23], topoisomerase inhibitor etoposide, taxol [24], the tumour necrosis 
factor (TNF) [25], and N-substituted benzamides like 3-chloroprocainamide and 
metoclopramide [26].
6. Plant secondary metabolites used IN conventional medicine
The WHO (World Health Organisation) defines a medicinal plant as a plant 
whose one or more parts, has constituents which can be applied for therapeutic 
purposes, or can act as precursors for chemical or pharmacological semi-synthesis. 
The parts of these medicinal plants such as the roots, tubers, barks, stems, leaves, 
flowers, seeds and fruits/grains, contains metabolites that are therapeutically active 
and are used to control or treat a disease condition.
Such non-nutritional chemical compounds or bioactive components in plants 
are called phytochemicals, the word –‘phyto’- from Greek, meaning ‘plant’. These 
phytoconstituents are responsible for protecting the plant against pest infestation 
or microbial infections [27]. A large variety of phytochemicals have been isolated 
and characterised from familiar sources including vegetables such as onion 
and broccoli, fruits like apples and grapes, spices such as nutmeg, pepper and 
turmeric, brews such as green tea, oolong tea and red wine [28], which possess 
strong antioxidant properties. These antioxidants in chemoprevention and treat-
ment of cancer and many more diseases by defending cells from damage by highly 
reactive oxygen compounds called ‘free radicals’. The common classes of plant 
secondary metabolites which have found their way into traditional and modern 
medicine include.
Quercetin, quercitrin and kaempferol are common flavonoids present in 
approximately seventy per cent of all plants. Flavonoids vary notably in their anti-
proliferative effectiveness depending on their structure. Kuntz et al. discovered that 
baicalein and myricetin induced apoptosis in Caco-2 and HT-29 cells [29]. Flavone, 
flavanone, flavonol, and isoflavone classes of flavonoids possess anti-proliferative 
effects in various cancer cell lines. Tangeretin found in the peel of tangerine is used 
extensively in Kampo medicines in Japan for treating cancer [21].
Solamargine, derived from a Chinese herb, Solanum incanum, has been noted 
to bring about apoptosis in human hepatocyte (Hep-3B) cells and normal skin 
fibroblast cells [30]. The alkaloids isolated from Tiliacora racemosa root with several 
bis-benzylisoquinoline alkaloids induced apoptosis in K-562 cells. Camptothecin 
(CPT), extracted from the stem wood of a Chinese tree, Camptotheca acuminata 
Decsne, Nyssaceae, works as a topoisomerase I inhibitor and induces apoptosis 
in PLB-985 (a human leukaemia cell line) cells [31]. The widely popular alka-
loids Vinblastine and vincristine are obtained from the Madagascar periwinkle, 
Catharanthus roseus (previously called Vinca rosea).
A new cytotoxic proteoglycan, which is related to the family of arabinogalactan 
proteins, isolated from the saffron plant (Crocus sativus L.) exhibited induction 
of apoptosis in cultured macrophages with a lesser non-cytotoxic concentration 
increasing the DNA laddering effect in apoptotic cells [32].
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A phytopreparation made from Viscum album L., is currently being used as an 
adjuvant in cancer therapy and is found to stimulate the immune system by improv-
ing the number and activity of neutrophils and NK cells [33]. The formulation 
has various toxic proteins including viscotoxins (VT) and mistletoe lectins (ML); 
induces the synthesis of cytokines such as IFN-g,TNF-a, IL-6 and 1 L-1 and exhib-
its cytostatic and cytotoxic effects on human lymphocytes and cultured tumour 
cells alike.
7. Why use plant-based drugs?
Plants are an important part of nature’s reservoir of medicinal agents and it is safe 
to say that they are nearly devoid of the side effects generally caused by synthetic 
drugs and chemical agents [34]. The WHO (World Health Organisation) reports 
that traditional medicine remains the chief mode of the treatment availed by 75–80% 
of the world’s total population for primary health care, particularly in developing 
countries. This can be attributed to improved compatibility with the human body, 
better cultural acceptability, and reduced or practically no side-effects [35, 36].
Although several compounds isolated from plants are in the process of being 
thoroughly tested for their anticancer properties, it is becoming acknowledged that 
the medicinal effects of plants are due to a complex interaction of the combination 
of compounds present in the whole plant (additive/synergistic and/or antagonistic) 
rather than the single constituents [27].
The review of the literature reveals that phytochemicals present in normal fruit 
and vegetables have harmonising and overlapping mechanisms of action, such 
as the modulation of detoxification enzymes, stimulation of the immune system, 
scavenging of free radicals, regulation of gene expression, hormone metabolism, 
antibacterial and antiviral properties. Bioactive plant extracts are valuable resources 
which aid in the development of less toxic, more efficient drugs to manage the 
progression of cancer.
A major problem concerning cancer chemotherapy is the development 
of resistance to cytotoxic agents. Overcoming multidrug resistance requires 
research into new antineoplastic agents. In this regard, natural products 
acquired from plants have shown to have high potential as drug reservoirs [37]. 
According to the WHO, around 80% of the population in developing countries 
rely on traditional medicines, mostly derived from plants for primary health 
care. The modern pharmacopoeia contains a minimum of 25% drugs which 
are derived from plants and several others which are synthetic analogues [38]. 
Hence, fighting cancers with natural compounds derived from plants present a 
very favourable alternative.
Phytochemicals display structural diversity and contain scaffolds tailored to bind 
and inhibit the functions of several key proteins. They have more chiral centres and 
varied ring systems when compared to synthetic drugs. This complexity is respon-
sible for increasing its target selectivity thereby reducing non-specific binding and 
adverse side effects [39].
8. Drug combinations and synergy
Drug combinations are widely used to treat deadly diseases such as AIDS and 
cancer. The main intention is to accomplish a reduction in dose and toxicity, syner-
gistic therapeutic effect and lessen or delay the induction of drug resistance.
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cell line Jurkat, human 
prostate cancer cell line 
DU145,
human colon cancer cell 
line DLD-1
[43]




Berberine Cisplatin Ovarian cancer cell line 
VCAR3
[45]
Doxorubicin Murine melanoma B16F10 
cells
[46]
Epirubicin T24 bladder cancer cells [47]
Evodiamine Human breast cancer 
MCF-7 cells
[48]
Tamoxifen Human breast cancer 
MCF-7 cells
[49]
Curcumin Cisplatin, etoposide, 
camptothecin, 
doxorubicin
Human and rat 
glioblastoma cell lines
[50]
Cisplatin, oxaliplatin Human ovarian carcinoma 






Human colon cancer cell 
line (HT-29)
[52]
Genistein Cisplatin Human pancreatic 
carcinoma cell line (BxPC-
3), murine xenograft 
model of BxPC-3 cells
[53]
Human pancreatic 
carcinoma cell lines 
(COLO-357 and L3.6pl)
[54]
Camptothecin Human cervical cancer 
cell line (HeLa), human 









Cisplatin Human ovarian cancer 
cell lines (SKOV3, CAOV3, 
and C200)
[57]















Indirubin Arylidene derivatives Human non‐small cell 
lung carcinoma cells
[60]
TRAIL Breast cancer and bladder 
carcinoma cell lines
[61]
Vinblastine HeLa cells [62]
Kaempferol TRAIL Human glioblastoma cell 
lines U87, U251, and U373
[63]




Mitoxantrone K562, LLC, K562, and KB 
Cell Lines
[65]
Luteolin Cisplatin Human liver cancer cells 
HepG2and Hep3B and 
human colorectal cancer 
cells HT29 and HCT116
[66]
Doxorubicin 4T1 and MCF-7 cells [67]
Rapamycin Human breast and 
ovarian cancer cell lines 
MDA-MB-453, AU565, 
SKOV3.ip1, HBL100, and 
MCF-7. MCF-7 and AU56
[68]
Quercetin Cisplatin Human laryngeal 
carcinoma cell line 
(Hep-2)
[69]
Doxorubicin Neuroblastoma and 









Murine fibrosarcoma cell 
lines
[71]
Resveratrol Cisplatin Wistar rats [72, 73]
Doxorubicin Human acute myeloid 




















Combinations studies with anti-cancer drugs in clinical practice.
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Synergistic interactions are essential in phytomedicine and explain the effec-
tiveness of extremely low doses of active constituents in herbal formulations. 
Traditional medicine works on the idea that a whole or partly purified plant extract 
offers improvements over a single isolated ingredient. Synergism also leads to 
toxicity reduction and minimization of resistance. Though vinblastine is success-
ful clinically by itself [40, 41], its use in combination with other anticancer agents 
is now under evaluation, mostly for the management of recurrent or advanced 
cancers that are resistant to conventional chemotherapy. The occurrence of clini-
cal drug resistance has emphasised the need to search for novel chemotherapeutic 
drugs and better combinations among these agents. Typically, synergy is considered 
to be greater than additive therapeutic effects when compared with the efficacy of 
each drug by itself. Recently, combination therapies being tested make use of drugs 
with different mechanisms of action, under the rationale that targeting two sepa-
rate pathways will result in improved cytotoxicity, whether additive or synergistic.
Several researchers have tried to enhance the potential of known anti-cancer 
agents like vinblastine and paclitaxel by the virtue of combination therapy with 
cisplatin, etoposide and doxorubicin. Table 1 gives a list of the combination stud-
ies performed on plant secondary metabolites with anti-cancer drugs in clinical 
practice which showed synergistic activity.
9. Future perspectives
Cancer cells have evolved multiple mechanisms to evade apoptosis and escape to 
other sites. Phytomedicine and ethnopharmacology have proved to be very effec-
tive in the prevention and treatment of human ailments. Plant extracts have several 
components with diverse possible intracellular targets. From literature, it is evident 
that plants have a long history of oral use in traditional medicine and hence, are 
considered safe and non-toxic and there lies a huge potential in developing crude 
whole plant extracts for the treatment of cancer, alone or in a combination with 
other drugs in clinical practice. It is also advisable to explore the potential of these 
plants as chemopreventive agents because of their antioxidant and free radical 
scavenging activity. However, before these plant metabolites can be used for cancer 
prevention or therapy, they must be subject to further testing which should include 
in vivo studies in animal models and clinical trials (randomised double-blind) in 
human subjects.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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